Amphioxus Cell Tech Inc is categorized under Commercial Medical Research in Houston, TX and active since 2006.
Amphioxus Cell Tech Inc was established in 2006, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 5172101 by the NAICS.
If you are seeking more information, feel free to contact James H Kelly at the company’s single location by writing to 11222 Richmond Avenue # 180, Houston, Texas TX 77082 or by phoning (281) 679-7900. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Amphioxus Cell Tech Inc |
| Contact Person: | James H Kelly |
| Address: | 11222 Richmond Avenue # 180, Houston, Texas 77082 |
| Phone Number: | (281) 679-7900 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5172101 |
| Share This Business: |
Amphioxus Cell Tech Inc was started in 2006 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 5172101. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact James H Kelly for inquiries that concern Amphioxus Cell Tech Inc by calling the company number (281) 679-7900, as your correspondence is most welcome. Additionally, the physical location of the single location of Amphioxus Cell Tech Inc can be found at the coordinates 29.727798,-95.574352 as well as the street address 11222 Richmond Avenue # 180 in Houston, Texas 77082.
For its online presence, you may visit Amphioxus Cell Tech Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.